Huntington's Disease
Huntington's disease (HD), also known as Huntington's chorea, is an inherited, incurable neurodegenerative disease that causes the progressive wasting away of nerve cells in the brain, leading to movement disorders, mental deterioration, and psychiatric symptoms. Symptoms typically begin between the ages of 30 and 50 and gradually worsen, leading to significant physical and cognitive decline.
Health Outcomes
- Activated Mitophagy Pathway
- Delayed Disease Progression
- Delayed Neurodegeneration
- Enhanced Auto-aggregation Ability
- Enhanced Autophagy
- Enhanced Neurological Disorder Management
- Impaired Vacuolar Function
- Improved Agility and Coordination Performance
- Improved Ataxia
- Improved Brain Function
- Improved Brain Health
- Improved Central Nervous System Function
- Improved Cognitive Orientation Function
- Improved Cytoprotection During Oxidative Stress
- Improved Motor Function
- Improved Motor Outcome
- Improved Motor Speed
- Improved Motor Symptom
- Improved Neurodegenerative Disease Symptoms
- Improved Neurodegenerative Disorder
- Improved Neurological Parameter
- Improved Neurological Symptoms
- Improved Neuronal Survival
- Increased 3-Hydroxykynurenine to Kynurenine Ratio
- Increased Autophagy
- Increased Brain Choline Level
- Increased Dopamine Transporter Binding
- Increased Neuronal Cell Survival
- Increased Plasma Kynurenic Acid Levels
- Maintained Cognitive Function
- Neuroprotection in Neurodegenerative Diseases
- No Significant Impact on Bacterial Community Composition or Diversity
- No Significant Improvement in Locomotor Activity
- No Significant Improvement in Memory Retention
- Preserved Wheel-Running Activity
- Prevented Neurometabolic Decline
- Prevention of Neurological Disorders
- Reduced 24-Hydroxycholesterol to Total Cholesterol Ratio
- Reduced Apoptosis
- Reduced Apoptosis Signal-Regulating Kinase 1 Level
- Reduced Central Nervous System Symptom Severity
- Reduced Cognitive Function
- Reduced Confusion and Bewilderment
- Reduced Cytoskeleton Disruption
- Reduced Glutamate Level
- Reduced Glutathione Loss
- Reduced Immune Cell Proliferation
- Reduced Laminin Level
- Reduced Locomotor Impairment
- Reduced Mitogen-Activated Protein Kinase Kinase 4 Level
- Reduced Motor Symptom
- Reduced N-acetylaspartate Level
- Reduced Neurodegeneration Symptoms
- Reduced Neurodegenerative Disease-Related Dysfunction
- Reduced Neurological Symptoms
- Reduced Neuronal Death
- Reduced Neurotoxicity
- Reduced Protein Damage
- Reduced Proteotoxicity
- Reduced Set-Shifting Reversal Error
- Regulated Microglial Activation
- Restored Neurodegeneration-Associated Metabolic Alterations
- Slowed Disease Progression
- Slowed Neuronal Damage Progression
- Stabilized Cell Membranes
- Stabilized Disease Progression
- Stabilized Neurofilament Light Chain Level
- Unchanged Survival Rate
- Worsened Cognitive Function
- Worsened Motor Function